UNSPSC 51434806: Elisartan

This classification denotes an angiotensin ii receptor antagonist with the molecular formula C27H29ClN6O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WCC8Z95027, chemically known as 1h-imidazole-5-carboxylic acid, 2-butyl-4-chloro-1-((2-(1h-tetrazol-5-yl)(1,1-biphenyl)-4-yl)methyl)-, 1-((ethoxycarbonyl)oxy)ethyl ester but generally known as elisartan, which bears US NIH Compound Identifier 183766.

UNSPSC 51434806 Elisartan, a Commodity code, represents prescription medications and active pharmaceutical ingredients that state and local governments procure for emergency medical services, public health programs, and institutional healthcare operations. Recent solicitations show state and local buyers sourcing specific branded and generic pharmaceuticals—including advanced life support medications, generic multi-source drugs, and over-the-counter products—through sealed competitive bidding, cooperative purchasing agreements, and direct-to-manufacturer initiatives. Issuing bodies include municipal fire and rescue departments, state health and human services agencies, and regional cooperative purchasing alliances serving multiple jurisdictions. Work under this code spans supply of individual medication line items with stringent expiration-date and shelf-life requirements, compliance with FDA, cGMP, and Drug Supply Chain Security Act standards, warehousing and logistics through authorized wholesalers, and performance reporting tied to administrative fee structures.

Activity concentrates in Florida, Texas, and Minnesota. The City of Tampa Fire Rescue solicited Advanced Life Support Medications (Bid No. 26-P-00188, IFB, due April 8, 2026) for four specific drug lines—Labetalol, Epinephrine, Adenosine, and Diltiazem—with estimated contract value of $40,000 and a one-year term plus renewal options under a Small Local Business Enterprise sheltered-market designation. The Texas Health and Human Services Commission issued a Request for Information (RFI No. HHS0017013, posted April 3, 2026) to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with contract effectiveness July 1, 2026 and a two-year initial term. Vendors face 3 percent administrative fees, comprehensive insurance requirements, and performance penalties for reporting or onboarding delays.